Oral and GI Mucositis — Part 2: Oral Mucositis Prevention and Management

5. Prevention of Oral Mucositis

5.1 Summary of Recommendations

The following table summarizes the evidence-based recommendations for oral mucositis prevention, synthesized from international guideline panels and systematic reviews.^{1 2 3 4}

5.2 Oral Cryotherapy

5.2.1 Mechanism

Oral cryotherapy (ice chips or crushed ice held in the mouth) produces local vasoconstriction of the oral mucosal vasculature. This reduces blood flow to the oral mucosa during the period of peak plasma drug concentration, thereby decreasing local tissue exposure to the cytotoxic agent. Cryotherapy is most effective for agents with short plasma half-lives (bolus administration) where the period of elevated drug concentration is well defined.^{1 5}

5.2.2 Indications and Protocols

5-Fluorouracil (bolus administration):

• Recommendation: Oral cryotherapy is recommended for prevention of oral mucositis in patients receiving bolus 5-FU ¹
• Protocol: Ice chips are placed in the mouth 5 minutes before bolus 5-FU injection. The patient should swish the ice chips continuously throughout the oral cavity, replenishing as they melt. Continue for at least 30 minutes from the time of drug administration.
• The rationale is based on the short half-life of bolus 5-FU (approximately 8–14 minutes). Thirty minutes of cryotherapy covers the period of peak plasma concentration and clearance of the initial distribution phase.
• Multiple randomized controlled trials have demonstrated significant reduction in all grades of oral mucositis (relative risk reduction approximately 50%).⁵

High-dose melphalan (HSCT conditioning):

• Recommendation: Oral cryotherapy is recommended for prevention of oral mucositis in patients receiving high-dose melphalan prior to autologous HSCT ¹
• Protocol: Ice chips beginning 5 minutes before melphalan infusion starts, continuing throughout the infusion and for at least 30 minutes (some protocols extend to 60–90 minutes) after the infusion completes. If the infusion is given over 30 minutes, the total cryotherapy duration is approximately 65–120 minutes.
• Extended cryotherapy duration (6 hours) has been studied and may further reduce mucositis severity, but patient tolerance becomes a limiting factor.⁶
• A pragmatic approach of 30 minutes before through 30–60 minutes after infusion completion is widely implemented and supported by evidence.

Edatrexate and other short-half-life bolus agents:

• Suggestion: Cryotherapy may be considered for other bolus-administered cytotoxic agents with short plasma half-lives ¹
• The principle of local vasoconstriction during peak drug exposure applies regardless of the specific agent, though formal evidence is limited to 5-FU and melphalan.

5.2.3 Practical Considerations

• Use plain ice chips (no flavoring agents that may irritate mucosa)
• Patients should be instructed to move ice throughout the mouth, not hold in one area
• Monitor for oral discomfort from cold; patients may take brief breaks if needed
• Contraindication: Patients receiving oxaliplatin should not use oral cryotherapy due to the risk of triggering or worsening oxaliplatin-induced cold-sensitive peripheral neuropathy and laryngopharyngeal dysesthesia
• Cryotherapy is inexpensive, widely available, and has minimal side effects beyond temporary discomfort

5.3 Low-Level Laser Therapy / Photobiomodulation (PBM)

5.3.1 Mechanism

Photobiomodulation (PBM), formerly known as low-level laser therapy (LLLT), involves the application of low-energy, non-thermal laser or LED light to mucosal tissues. The proposed mechanisms include:^{7 8}

• Stimulation of mitochondrial cytochrome c oxidase, increasing ATP production and cellular metabolism
• Reduction of NF-kB-mediated pro-inflammatory cytokine expression
• Promotion of fibroblast proliferation and collagen synthesis
• Enhancement of angiogenesis and neovascularization
• Stimulation of epithelial cell migration and proliferation
• Reduction of ROS levels

5.3.2 Recommendations and Evidence

Recommendation: Intraoral PBM is recommended for prevention of oral mucositis in patients receiving:

• HSCT conditioned with high-dose chemotherapy (with or without TBI) ¹
• Head and neck radiation therapy (with or without concurrent chemotherapy) ¹

The evidence supporting PBM for mucositis prevention in HSCT and head and neck radiation has been evaluated in multiple randomized controlled trials and systematic reviews, consistently demonstrating reductions in the incidence and severity of oral mucositis, pain scores, duration of severe mucositis, and opioid requirements.^{7 8}

5.3.3 Treatment Parameters

The effectiveness of PBM is wavelength-, power density-, and energy density-dependent. The following parameters have been evaluated in clinical studies and are recommended based on available evidence.^{7 8}

Example protocol (HSCT setting):

• Wavelength: 660 nm (red diode laser)
• Power: 40 mW
• Spot size: ~1 cm²
• Energy density: 4 J/cm² per point
• Time per point: ~100 seconds (to deliver 4 J/cm² at 40 mW to ~1 cm² spot)
• Sites: 6–8 intraoral sites bilaterally
• Schedule: Daily beginning on the first day of conditioning through day +2 to day +7 post-transplant (or until engraftment)

Example protocol (head and neck radiation setting):

• Wavelength: 660 nm or 810 nm
• Power: 100 mW
• Spot size: ~1–4 cm²
• Energy density: 2–4 J/cm² per point
• Schedule: Prior to or immediately after each radiation fraction, five days per week throughout the radiation course

5.3.4 Practical Considerations

• PBM must be delivered by trained personnel; certification programs exist
• Protective eyewear is mandatory for both patient and operator (laser safety goggles matched to wavelength)
• PBM should not be applied directly to tumor sites when the tumor is within the oral cavity (theoretical concern of tumor photostimulation, though clinical evidence of harm is lacking)
• Equipment cost varies widely; multibeam LED devices and intraoral scanning devices may reduce treatment time
• PBM is considered safe with no established adverse effects in the published literature

5.4 Palifermin (Recombinant Human Keratinocyte Growth Factor-1)

5.4.1 Mechanism

Palifermin is a recombinant, truncated form of human keratinocyte growth factor (KGF, also designated FGF-7). It acts on the KGF receptor (FGFR2b), which is expressed on epithelial cells but not on cells of hematopoietic or mesenchymal origin. Palifermin stimulates:^{9 10}

• Epithelial cell proliferation, resulting in increased mucosal thickness
• Differentiation and maturation of epithelial cells
• Upregulation of cytoprotective pathways (including Nrf2-mediated antioxidant response)
• Enhanced DNA repair mechanisms in epithelial cells
• Increased production of mucosal antimicrobial peptides

5.4.2 Indications and Dosing

Recommendation: Palifermin is recommended for the prevention of oral mucositis in patients with hematologic malignancies receiving myeloablative conditioning with total body irradiation (TBI) prior to autologous HSCT. ^{1 9}

Critical timing considerations:

• Palifermin should be given at least 24 hours before and at least 24 hours after the most recent dose of chemotherapy. Administration within 24 hours of chemotherapy may increase the severity of mucositis due to palifermin-stimulated epithelial cell proliferation during active cytotoxic exposure.
• Do not administer palifermin within 24 hours before or after chemotherapy.

5.4.3 Evidence and Limitations

• The pivotal randomized, double-blind, placebo-controlled trial demonstrated that palifermin significantly reduced the incidence of WHO Grade 3–4 oral mucositis (63% vs. 98% with placebo; p < 0.001), the duration of severe mucositis, and the requirement for opioid analgesia and parenteral nutrition.⁹
• The evidence is strongest and the approved indication is specific to TBI-based myeloablative conditioning for autologous HSCT in hematologic malignancies.
• Evidence for palifermin in non-TBI HSCT conditioning, allogeneic HSCT, and head and neck radiation therapy is less robust. International guidelines suggest that palifermin may be considered in these settings but do not provide a strong recommendation.¹
• Palifermin should not be used in patients with non-hematologic malignancies in which KGF receptors are expressed on tumor cells (theoretical risk of tumor stimulation). In practice, this is primarily a concern with epithelial carcinomas.

5.4.4 Adverse Effects

5.5 Basic Oral Care Protocol

Recommendation: A systematic oral care protocol is recommended for all cancer patients at risk for mucositis. This is considered good clinical practice and is the foundation of mucositis management.^{1 2 3}

5.6 Benzydamine Oral Rinse

Benzydamine hydrochloride is a topical non-steroidal anti-inflammatory drug with analgesic, anti-inflammatory, and local anesthetic properties.¹

• Suggestion: Benzydamine oral rinse may be considered for prevention of oral mucositis in patients receiving moderate-dose radiation therapy (up to 50 Gy) to the head and neck without concurrent chemotherapy.
• Dose: 0.15% benzydamine HCl oral rinse, 15 mL, swish and spit, every 2–3 hours during waking hours
• Begin at the start of radiation therapy and continue throughout the treatment course
• Note: Benzydamine is widely available in Europe, Canada, and many other countries but is not approved or commercially available in the United States. In the U.S., compounding pharmacies may be able to prepare it.
• The evidence is less convincing for radiation doses >50 Gy or concurrent chemoradiation.

5.7 Agents with Evidence Against Use

The following agents have been specifically evaluated and are not recommended for mucositis prevention based on negative trial evidence or evidence of lack of efficacy:^{1 2}

6. Assessment and Monitoring of Oral Mucositis

6.1 Assessment Schedule

6.2 Assessment Components

Each mucositis assessment should include:

1. Visual oral examination: Systematic examination of all intraoral mucosal surfaces (lips, buccal mucosa, tongue [dorsal, ventral, lateral], floor of mouth, hard palate, soft palate, oropharynx); note erythema, edema, ulceration, pseudomembrane, hemorrhage
2. Pain assessment: Numeric rating scale (NRS 0–10) or visual analog scale (VAS) for oral pain at rest and with swallowing
3. Functional assessment: Ability to eat, drink, swallow, and speak
4. Dietary intake: Caloric and fluid intake; weight monitoring
5. Grading: Assign grade using WHO, CTCAE, or OMAS as appropriate for the care setting
6. Infection assessment: Evaluate for signs of secondary infection (candidiasis — white plaques; HSV — vesicles/grouped ulcers; bacterial superinfection)
7. Salivary function: Assess for xerostomia; quantify if indicated (whole saliva flow rate)

7. Pain Management in Oral Mucositis

7.1 Principles

Oral mucositis pain is frequently the most distressing symptom for patients and is the primary driver of dose modifications, treatment interruptions, opioid use, and reduced quality of life. A stepwise, multimodal approach is recommended.^{2 11}

7.2 Topical Analgesics

7.3 Systemic Analgesics

A stepwise approach following WHO analgesic ladder principles is recommended for oral mucositis pain that is not adequately controlled with topical agents alone.¹¹

Step 1: Mild Pain (NRS 1–3)

Step 2: Moderate Pain (NRS 4–6)

Step 3: Severe Pain (NRS 7–10)

Adjuvant Agents

8. Nutritional Support

8.1 Nutritional Impact of Mucositis

Oral mucositis directly impairs nutritional intake through pain, dysphagia, dysgeusia, and mechanical obstruction. Grade 3–4 mucositis frequently requires modification or complete cessation of oral intake. Malnutrition during cancer therapy increases infection risk, impairs wound healing, reduces treatment tolerance, and worsens outcomes.¹²

8.2 Nutritional Assessment and Intervention

8.3 Enteral Feeding Considerations in Head and Neck Cancer

• Prophylactic gastrostomy tube (PEG/RIG) placement is commonly performed before head and neck radiation in patients expected to develop Grade 3+ mucositis and/or significant weight loss (>10% body weight)
• Benefits: maintains nutritional status, hydration, and medication delivery during severe mucositis
• Timing: ideally placed >=7–10 days before radiation initiation to allow tract maturation
• Reactive nasogastric tube (NGT) placement is an alternative for patients who did not receive a prophylactic gastrostomy; NGTs are less comfortable for extended use but avoid the need for a surgical procedure
• Swallowing exercises should continue throughout treatment even if the patient is tube-fed, to prevent long-term dysphagia from disuse and fibrosis

9. Infection Management in the Context of Oral Mucositis

9.1 Oral Candidiasis

Oral candidiasis is the most common secondary infection complicating oral mucositis, occurring in 30–70% of patients receiving cancer therapy, especially those who are neutropenic, receiving corticosteroids, or have xerostomia.¹³

Clinical presentation: White, removable plaques (pseudomembranous candidiasis); erythematous, atrophic areas (erythematous candidiasis); angular cheilitis. May be difficult to distinguish from mucositis pseudomembranes.

9.2 Herpes Simplex Virus (HSV) Reactivation

HSV seropositive patients undergoing HSCT or intensive chemotherapy (e.g., AML induction) are at high risk for HSV reactivation in the oral mucosa, which can be clinically indistinguishable from or superimposed on cytotoxic mucositis.¹⁴

Clinical clues suggesting HSV reactivation:

• Clustered vesicles (may be absent in immunocompromised patients)
• Ulcers on keratinized mucosa (hard palate, attached gingiva, dorsal tongue) — mucositis preferentially affects non-keratinized mucosa
• Sudden worsening of mucositis or failure to heal as expected
• Positive HSV PCR or direct fluorescent antibody (DFA) from lesion swab

9.3 Bacterial Infections

• Ulcerated mucosa in neutropenic patients is a primary portal of entry for viridans group streptococci, gram-negative bacilli, and anaerobes
• Management: Febrile neutropenia protocols (see Febrile Neutropenia guideline); mucositis is a risk factor for bacteremia and should prompt close monitoring
• Topical antibacterial agents (e.g., polymyxin-tobramycin-amphotericin [PTA] paste/lozenges) have been studied for selective oral decontamination; evidence is mixed and this approach is not routinely recommended by most guideline panels

10. Multidisciplinary Team Approach

Effective mucositis management requires coordination among multiple disciplines.^{2 15}

11. Patient Education and Self-Care

11.1 Key Education Points

All patients at risk for mucositis should receive structured education covering:^{2 15}

1. What to expect: Timeline of mucositis onset, peak severity, and expected healing; normalize the experience while emphasizing the importance of reporting symptoms
2. Oral hygiene: Demonstrate gentle toothbrushing technique, bland rinse preparation, and lip care
3. Dietary modifications: Avoid irritants (alcohol, tobacco, spicy/acidic/rough foods, very hot or very cold foods and beverages); choose soft, moist, lukewarm foods; high-protein, high-calorie snacks; use a straw for liquids if helpful
4. Pain reporting: Use pain scale (NRS 0–10) to describe pain; do not underreport; early intervention is more effective
5. Infection signs: Report fever, new or worsening oral lesions, white patches, difficulty swallowing, or neck swelling immediately
6. Hydration: Maintain fluid intake >=1.5–2 L/day; sip water frequently
7. When to seek care: Fever, inability to eat or drink, uncontrolled pain, signs of dehydration (decreased urine output, dizziness), bleeding from oral lesions
8. Avoid: Commercial mouthwashes containing alcohol; hydrogen peroxide rinses; lemon-glycerin swabs (irritating and drying); tobacco and alcohol

References